On Monday, SEBI excluded the API manufacturer PAR-medicines and chemicals to continue with the proposed malaise sale of its core activities to a promoter-related entity, stating excellent facie irregularities in valuation, communication of shareholders and voting process. In an interim sequence, Sebi maintained the PAR-Medicines and Chemicals Ltd (PDCL) based in Vadodara of performing the […]
